Lassen Therapeutics is a Frazier-founded company developing antibodies as potential treatments for fibrotic and rare diseases as well as cancer. The company’s lead candidate is LASN-01, a potentially first and best-in-class monoclonal antibody licensed from CSL Limited that targets IL-11 receptor alpha (IL-11R). IL-11 is a central mediator of fibrosis and by blocking IL-11’s interaction with its receptor, LASN-01 may reduce fibrosis and thereby improve outcomes for patients with fibrotic diseases. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
Location: United States, California, San Diego
Total raised: $85M
Investors 4
| Date | Name | Website |
| - | DC Investm... | dcinvestme... |
| - | Frazier Li... | frazierls.... |
| 10.01.2024 | Longitude ... | longitudec... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.12.2023 | Series B | $85M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 20.12.2023 | Lassen Therapeutics Closes $85M Series B Financing | Lassen Therapeutics, a San Diego, CA-based clinical stage biotech company, raised $85M in Series B f... | finsmes.co... |
| - | Lassen Therapeutics | “Lassen Therapeutics is developing novel, best-in-class biotherapeutics to improve the lives of pati... | fastfounde... |